Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23604940 | 0.97 | MAP3K5 (0.32) | MAP3K5 | |
| SCHEMBL24115412 | 0.95 | MAP3K5 (0.33) | MAP3K5 | |
| SCHEMBL23962156 | 0.94 | MAP3K5 (0.33) | LMNAKDM4EALOX15MAP3K5 | |
| SCHEMBL20998935 | 0.92 | MAP3K5 (0.32) | MAP3K5 | |
| SCHEMBL21152761 | 0.91 | MAP3K5 (0.33) | MAP3K5 | |
| SCHEMBL22692410 | 0.91 | GRM5 (0.31) | MAP3K5 | |
| SCHEMBL23961990 | 0.90 | SLC9A1 (0.33) | — | |
| SCHEMBL24252206 | 0.89 | — | — | |
| SCHEMBL20998897 | 0.89 | MAP3K5 (0.34) | MAP3K5 | |
| SCHEMBL26242503 | 0.89 | CRHR1 (0.33) | KDM4EALOX15MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047716-A1 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | SUTRO BIOPHARMA, INC. | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047716-A1 | COMBINATION THERAPIES WITH ANTI-FOLATE RECEPTOR ANTIBODY CONJUGATES | FOLR1, FOLR2, DHFR | LMNA 3935/4885KDM4E 3777/4885ALOX15 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.